103 related articles for article (PubMed ID: 28011985)
1. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
Gilli S; Novak U; Taleghani BM; Baerlocher GM; Leibundgut K; Banz Y; Zander T; Betticher D; Egger T; Rauch D; Pabst T
Ann Hematol; 2017 Mar; 96(3):421-429. PubMed ID: 28011985
[TBL] [Abstract][Full Text] [Related]
2. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Wu R; Ma L
Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
[TBL] [Abstract][Full Text] [Related]
3. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
Plante MÉ; Feng X; Boudreault JS
Leuk Lymphoma; 2023; 64(7):1234-1242. PubMed ID: 37154396
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Efficacy of Modified BeEAM(Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country.
Ramzi M; Vafaie E; Haghighinejad H; Imran H
Int J Hematol Oncol Stem Cell Res; 2023 Apr; 17(2):106-113. PubMed ID: 37637764
[No Abstract] [Full Text] [Related]
5. A low thrombospondin-1 serum concentration is related to increased bacteremia risk in lymphoma patients treated with BeEAM/BEAM conditioning regimen and autologous stem cell transplantation.
Kościelny K; Mikulski D; Nowicki M; Wyka K; Misiewicz M; Perdas E; Wierzbowska A; Fendler W
Transpl Infect Dis; 2024 Feb; 26(1):e14212. PubMed ID: 38112043
[TBL] [Abstract][Full Text] [Related]
6. BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.
Keil F; Müller AMS; Berghold A; Riedl R; Buxhofer-Ausch V; Schuster J; Vorburger C; Böhm A; Panny M; Nösslinger T; Greil R; Samaras P; Bencker C; Rütti M; Pabst T
EClinicalMedicine; 2023 Dec; 66():102318. PubMed ID: 38024477
[TBL] [Abstract][Full Text] [Related]
7. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM; Devine SM; Andritsos LA
Bone Marrow Transplant; 2014 Oct; 49(10):1323-9. PubMed ID: 25068419
[TBL] [Abstract][Full Text] [Related]
8. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
Ogawa Y; Izutsu K; Kiguchi T; Choi I; Takatsuka Y; Ando K; Suzumiya J;
Int J Hematol; 2017 May; 105(5):631-637. PubMed ID: 28160213
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety experience with bendamustine for injection in a real-world setting.
Martin P; Barr PM; James L; Pathak A; Kahl B
Expert Opin Drug Saf; 2017 Jun; 16(6):647-650. PubMed ID: 28395515
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.
Berentsen S; Randen U; Oksman M; Birgens H; Tvedt THA; Dalgaard J; Galteland E; Haukås E; Brudevold R; Sørbø JH; Næss IA; Malecka A; Tjønnfjord GE
Blood; 2017 Jul; 130(4):537-541. PubMed ID: 28533306
[TBL] [Abstract][Full Text] [Related]
12. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT; Shanafelt TD; Leis JF; LaPlant B; Call T; Pettinger A; Hanson C; Erlichman C; Habermann TM; Reeder C; Nikcevich D; Bowen D; Conte M; Boysen J; Secreto C; Lesnick C; Tschumper R; Jelinek D; Kay NE; Ding W
Am J Hematol; 2017 Aug; 92(8):759-763. PubMed ID: 28402581
[TBL] [Abstract][Full Text] [Related]
13. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
Berdeja JG; Bauer T; Arrowsmith E; Essell J; Murphy P; Reeves JA; Boccia RV; Donnellan W; Flinn I
Br J Haematol; 2017 Apr; 177(2):254-262. PubMed ID: 28169430
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
Chantepie SP; Garciaz S; Tchernonog E; Peyrade F; Larcher MV; Diouf M; Fornecker LM; Houot R; Gastinne T; Soussain C; Malak S; Lemal R; Delette C; Ibrahim A; Gac AC; Reboursière E; Vilque JP; Bekadja MA; Casasnovas RO; Gressin R; Guidez S; Coso D; Herbaux C; Yakoub-Agha I; Bouabdallah K; Durot E; Damaj G
Am J Hematol; 2018 Jun; 93(6):729-735. PubMed ID: 29473209
[TBL] [Abstract][Full Text] [Related]
17. Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.
Dolan SB; Patel M; Hampton LM; Burnett E; Ehlman DC; Garon J; Cloessner E; Chmielewski E; Hyde TB; Mantel C; Wallace AS
J Infect Dis; 2017 Jul; 216(suppl_1):S152-S160. PubMed ID: 28838188
[TBL] [Abstract][Full Text] [Related]
18. [A Case of Cystoid Macular Edema Secondary to Albumin-Bound Paclitaxel Therapy].
Ito T; Deguchi K; Yoshii K; Kashii M
Gan To Kagaku Ryoho; 2017 Jul; 44(7):599-602. PubMed ID: 28790265
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
